A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators

A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators

Advances in antiviral therapy have dramatically improved the therapeutic effects on HIV type 1 (HIV-1) infection. However, even with potent combined antiretroviral therapy, HIV-1 latently infected cells cannot be fully eradicated. Latency-reversing agents (LRAs) are considered a potential tool for e...

Full description

Bibliographic Details
Main Authors: Kouki Matsuda, Takuya Kobayakawa, Ryusho Kariya, Kiyoto Tsuchiya, Shoraku Ryu, Kohei Tsuji, Takahiro Ishii, Hiroyuki Gatanaga, Kazuhisa Yoshimura, Seiji Okada, Akinobu Hamada, Hiroaki Mitsuya, Hirokazu Tamamura, Kenji Maeda
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Microbiology
Subjects:
HIV-1 reservoirs
HIV-1 latently infected cells
diacylglycerol-lactone
protein kinase C activator
HIV-1
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2021.636276/full

Internet

https://www.frontiersin.org/articles/10.3389/fmicb.2021.636276/full

Similar Items